Viewing nowCombinationPimaduet Tablet 60/2.5 mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.

MFDS item code 202300122 · Approved 2023.01.06 · Insurance code 663608700
Treatment of essential hypertension not controlled with fimasartan monotherapy
This medication helps to control blood pressure more effectively in patients with essential hypertension whose blood pressure is not adequately controlled with Pimasartan Potassium monotherapy. It acts by dilating blood vessels to reduce blood pressure and can improve blood pressure control as combination therapy in cases where monotherapy is insufficient. Hence, Pimasartan Potassium is used in the management of blood pressure in essential hypertension.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using fimasartan; however, direct switching to this medicine may be considered if blood pressure is not controlled, as follows. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is required for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with this medicine containing fimasartan 30 mg. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication may cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be taken by individuals with an allergy to its active ingredients or similar substances, those who are pregnant or nursing, patients undergoing dialysis, those with moderate to severe liver impairment, patients with bile duct obstruction, certain kidney diseases, or diabetic nephropathy. Caution is required for individuals with low blood volume or salt deficiency, impaired kidney function, renovascular hypertension, heart valve diseases, severe hypotension, elderly patients, or those sensitive to specific dyes. Symptoms such as dizziness, headache, facial swelling, urinary disorders, insomnia, and flushing may occur during use, and rare but serious side effects may emerge; consult a healthcare professional immediately if any abnormal symptoms arise. In cases of hypotension or electrolyte imbalance, blood pressure may drop sharply, especially during the initial dose; therefore, close monitoring is required. This medication may interact with other antihypertensives, diuretics, potassium-sparing diuretics, certain antibiotics, analgesics, etc., so it is important to inform your healthcare provider about any concurrent medications. If pregnant or nursing, this medication should be avoided or taken only after consulting a doctor to determine the necessity of use. Safety and efficacy in children under 18 years have not been established; therefore, it is advisable not to use it in this age group. In cases of overdose, severe hypotension, cardiac arrhythmias, etc., may occur, necessitating immediate emergency treatment, and self-treatment should be avoided. Keep this medication out of the reach of children, and be careful not to transfer it to another container, as this may compromise quality and increase the risk of accidents. Dizziness or drowsiness may occur when driving or operating dangerous machinery during treatment, so caution is advised. Patients with heart failure or impaired liver function require special caution when taking this medication, and dosage adjustments may be necessary based on their condition.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that protects it from light and air, at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness over time.
Yellow, rounded square, film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.